Overseas Studies May Not Be Worth Oversight Costs, Consultants Suggest
This article was originally published in The Pink Sheet Daily
Executive Summary
Overseas clinical trials could save companies money, but consultants on a regulatory panel at the Biotechnology Industry Organization's Mid-America VentureForum in Cleveland suggested such studies might not be worth the oversight costs
You may also be interested in...
Adaptive Clinical Trials Should Still Be Designed “Conservatively,” Integra Consultant Says
Assuming a study will need to be large could lead to cost-savings if stopped early, while starting with a small design could result in problems if expansion is needed.
Novartis Institute For Tropical Diseases Could Have TB Drug In Clinic By Late 2007
Singapore-based institute is also looking at dengue fever and malaria, exec says in interview with “The Pink Sheet” DAILY.